LCT Appoints Paris Brooke As General Manager
10 March 2005, Australia:
LCT appoints Paris Brooke as General Manager
Living Cell Technologies (ASX: LCT) today announced the appointment of Ms Paris Brooke to the position of General Manager.
Ms Brooke is a highly qualified biotechnology executive who specialises in business positioning, strategic advice and stakeholder management of biotechnology companies.
Ms Brooke's role will be effective from 1 April and she will be based in Melbourne. Her immediate attention will focus on building the Australian corporate office of LCT and raising the awareness of LCT's technology to sufferers of diabetes, Huntington's disease and haemophilia.
Previous to this appointment, Ms Brooke held the position of Policy and Communication Manager at AusBiotech - Australia's Biotechnology Industry Organisation, where she drove federal industry advocacy programs to position the biotechnology industry.
"LCT is one of Australia's most promising biotechnology companies and I am excited to become involved in it," said Ms Brooke.
Mr David Collinson, Chief Executive Officer of LCT, commented, "The appointment of Paris begins a new phase of development for LCT. We are delighted to have attracted someone with Paris' experience, strong reputation and deep commitment to the Australian biotechnology industry.
This is another important accomplishment for LCT. Along with our announcement of the cashless acquisition of Theracyte and Baxter's R&D worth an estimated US$90 million last week, and the successful preliminary results for DiaBCell last month, we are now poised for a momentum of activity," he added.
Ms Brooke has also been instrumental in the biotechnology sector through her management of businesses including SDA Biotech, a life science communications group, and BioNetwork, the first national magazine dedicated to biotechnology.
About LCT: www.lct.com.au
LCT is an ASX listed biotechnology company (ASX: LCT). Living Cell Technologies Ltd (LCT) began its business to develop and commercialise cell therapies for the treatment of a wide variety of diseases in 1987. The company has operating companies in New Zealand and Rhode Island, US.
LCT's technology has potential application for the treatment of conditions caused by a deficiency of specific cell function. The company has three products under development - NeurotrophinCell for Huntington's, Fac8Cell for haemophilia and DiaBCell for diabetes.